Carbon To Carbon Unsaturation In R Patents (Class 514/627)
  • Publication number: 20130059911
    Abstract: There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer.
    Type: Application
    Filed: November 1, 2012
    Publication date: March 7, 2013
    Applicant: Centre de Recherche sur les Biotechnologies Marines
    Inventor: Centre de Recherche sur les Biotechnologies Mari
  • Publication number: 20130023510
    Abstract: The present invention provides arachidonic acid (AA) analogs and compositions containing those analogs as active agents for use in analgesic treatments. Various methods of manufacturing the inventive compounds are provided and pharmaceutical formulations, including injectable and oral dosages, are described. Certain analogs are additionally useful as antipyretic compositions and in related fever reducing treatments.
    Type: Application
    Filed: May 25, 2012
    Publication date: January 24, 2013
    Applicant: Cytometix, Inc.
    Inventors: Lane Brostrom, John R. Falck
  • Publication number: 20130011345
    Abstract: The present invention has discovered that amide compounds represented by Formula I set forth below and isomers thereof have unexpected and advantageous flavor enhancement and modification properties: The amide compounds of the present invention can be used to enhance or modify the flavor of orally consumable compositions, such as foodstuff, chewing gums, dental and oral hygiene products, and medicinal products.
    Type: Application
    Filed: July 8, 2011
    Publication date: January 10, 2013
    Inventors: Adam Jan Janczuk, Zhihua Liu
  • Publication number: 20130012592
    Abstract: The present invention relates to an agomelatine hydrobromide hydrate of formula I wherein X is Br, preparation and use thereof, and to pharmaceutical compositions containing it. The agomelatine hydrobromide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps.
    Type: Application
    Filed: March 17, 2011
    Publication date: January 10, 2013
    Applicant: Les Laboratoires Servier
    Inventors: Hanbin Shan, Zhedong Yuan, Xueyan Zhu, Peng Zhang, Hongjuan Pan, Xiong Yu
  • Publication number: 20130005691
    Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
    Type: Application
    Filed: June 13, 2012
    Publication date: January 3, 2013
    Inventor: Annabelle Gallois-Bernos
  • Publication number: 20130005805
    Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
    Type: Application
    Filed: June 13, 2012
    Publication date: January 3, 2013
    Inventors: Annabelle Gallois-Bernos, Frank F. Molock, JR., Carrie L. Davis, Kathrine Osborn Lorenz, James K. Young, Kristy L. Canavan, Fang Lu
  • Publication number: 20120321727
    Abstract: Disclosed are edible formulations, for example, edible films and gummi confectioneries, that mask the taste of semen. The films and confectioneries include a composition that upon activation in the oral cavity provides a lasting taste masking effect that endures for up to 20 minutes. The composition includes a film former or gelling agent, an effective amount of a protein masker, and an effective amount of a bitter masker. The composition may also include a flavoring agent, sweetening agents, and sensates.
    Type: Application
    Filed: April 25, 2012
    Publication date: December 20, 2012
    Applicant: ACME SPECIALTY PRODUCTS, LLC
    Inventors: Robert J. Windschauer, Teresa T. Virgallito
  • Patent number: 8334408
    Abstract: Compounds of formula wherein the variables are defined in the specification, are used in compositions which stimulate T cell responses.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: December 18, 2012
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
  • Publication number: 20120309836
    Abstract: Compositions are provided that contain a TRPV1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. Method of using the compositions for reducing nociceptive nerve fiber function in subjects, and for treatment of capsaicin-responsive conditions are also provided.
    Type: Application
    Filed: August 14, 2012
    Publication date: December 6, 2012
    Applicant: NeurogesX, Inc.
    Inventors: Naweed Muhammad, Gene C. Jamieson, Keith R. Bley, Sanjay Chanda
  • Publication number: 20120277305
    Abstract: The invention relates to fatty acid guanidine or salicylate guanidine derivatives; compositions comprising an effective amount of a fatty acid guanidine or salicylate guanidine derivative; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid guanidine or salicylate guanidine derivative.
    Type: Application
    Filed: April 27, 2012
    Publication date: November 1, 2012
    Applicant: CATABASIS PHARMACEUTICALS, INC.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu, Amal Ting
  • Publication number: 20120263808
    Abstract: For enhancing bioavailability, a composition is administered comprising a Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) agonist with a combined Scoville Heat Unit (SHU) milligram (mg) dose in the range of 280,000 to 400,000 SHU mg.
    Type: Application
    Filed: April 13, 2012
    Publication date: October 18, 2012
    Inventor: W. Matthew Warnock
  • Publication number: 20120252900
    Abstract: Grease-like compositions are provided for repelling insects and preventing undesirable behavior in hoofed animals. The compositions utilize nontoxic mineral, synthetic, or vegetable oil based gels containing silica, clay, urea, polytetrafluoroethylene, or metallic soap thickeners and capsaicin.
    Type: Application
    Filed: April 4, 2012
    Publication date: October 4, 2012
    Applicants: Tomlin Scientific, Inc., PiGNX, Inc.
    Inventors: Richard Numata, Ryan Willey
  • Publication number: 20120238624
    Abstract: Formulations and methods are provided for the treatment of pain, and neuropathic pain in particular. The formulations are eutectic mixtures of a capsaicinoid and a local anesthetic agent and/or an anti-pruritic agent.
    Type: Application
    Filed: September 14, 2011
    Publication date: September 20, 2012
    Inventor: Manoj Maniar
  • Patent number: 8263059
    Abstract: The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleansing composition, e.g., a composition in which capsaicin is soluble.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: September 11, 2012
    Assignee: NeurogesX, Inc.
    Inventors: Arturo J. Angel, Larry W. Litle, Keith R. Bley, Allan L. Wilcox, Gene Curtis Jamieson, Naweed Muhammad
  • Patent number: 8263661
    Abstract: The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: September 11, 2012
    Assignees: The Regents of the University of California, Oregon Health & Science University
    Inventors: Thomas S. Scanlan, Martin J. Kelly, Jian Qiu, Sandra Tobias, Oline K. Ronnekleiv
  • Publication number: 20120219621
    Abstract: A composition with enhanced thermogenic activity and the use thereof in the prevention and treatment of obesity Pharmaceutical compositions of a dietary supplement or medical device, useful for the treatment and prevention of overweight and obesity and metabolic syndrome comprising: a) menthol or a peppermint essential oil comprising menthol, in association with one or more components having a thermogenetic activity, selected from: b1) capsaicin or a capsacinoid derived from Capsicum genus or a Capsicum extract containing capsaicin and/or capsacinoids; b2) a sulphur containing active principle derived from the Allium genus or an Allium extract containing it; b3) a catechin active substance derived from the genus Camellia or a Camellia extract containing it. The menthol and mint essential oil have a potentiating action on the biological activities of the other aforementioned components.
    Type: Application
    Filed: October 11, 2010
    Publication date: August 30, 2012
    Applicant: MEDESTEA BIOTECH S.P.A.
    Inventor: Mariana Gabriela Alvarez Favela
  • Patent number: 8252520
    Abstract: The present invention provides methods and compounds for inhibiting HEC1 activity for the treatment of diseases involving cell hyperproliferation, e.g. cancer. The present invention also provides methods of identifying compounds for inhibiting HEC1 activity.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: August 28, 2012
    Assignee: Taivex Therapeutics Corporation
    Inventors: Wen-Hwa Lee, Phang-Lang Chen, Yumay Chen
  • Publication number: 20120214858
    Abstract: Imidamide (amidine) analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumors.
    Type: Application
    Filed: August 16, 2010
    Publication date: August 23, 2012
    Applicant: University of Virginia Patent Foundation
    Inventors: Kevin R. Lynch, Timothy L. Macdonald, Thomas P. Mathews, Andrew Kennedy, Yugesh Kharel
  • Publication number: 20120213869
    Abstract: A pain relieving composition that includes an anesthetic in the range of 0.5%-7.0% by weight (“w/w”), an anti-inflammatory agent in the range of 1.0%-11.0% w/w, a moisturizing agent in the range of 0.5%-12.0% w/w, a humescent in the range of 0.5%-13.0% w/w, a penetration enhancing agent in the range of 0.5%-7.0%, and a carrier solvent in the range of 40.0%-97.0% w/w to be used before and/or after procedures which cause damage to human skin.
    Type: Application
    Filed: February 23, 2011
    Publication date: August 23, 2012
    Applicant: MISS SMARTY PANTS ENTERPRISES, INC.
    Inventor: Edna Ma
  • Publication number: 20120208878
    Abstract: The object of the invention is to find the actions of the crude drugs contained in Daikenchuto or their components and the synergistic effect of the components with one another or with other pharmacologically active substances, and to provide new drugs or pharmaceutical compositions based on the findings. The invention is directed to intestinal peristaltic motility-enhancers comprising an effective amount of hydroxy-?-sanshool or a plant containing the same or an extract thereof; compositions comprising a combination of hydroxy-?-sanshool or a plant containing the same or an extract thereof and capsaicin or a plant containing the same or an extract thereof or bethanechol or a salt thereof; as well as a method for improving intestinal motility which comprises administering the composition to a patient.
    Type: Application
    Filed: February 10, 2011
    Publication date: August 16, 2012
    Applicant: TSUMURA & CO.
    Inventor: Nobuhiro OHTAKE
  • Patent number: 8236987
    Abstract: The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: August 7, 2012
    Assignees: The Regents of the University of California, Oregon Health & Science University
    Inventors: Thomas S. Scanlan, Toru Iijima
  • Patent number: 8227516
    Abstract: The present invention relates to compounds as inhibitors of enzymes having histone deacetylase activity, to the processes for the preparation of those compounds, and to their use for the treatment of diseases which are associated with hypoacetylation of histones and/or other molecules, or in which induction of hyperacetylation has a beneficial effect for example by inhibition of proliferation and/or induction of differentiation and/or induction of apoptosis in transformed cells, such as cancer. Furthermore, the compounds are useful for the treatment of other proliferative diseases, for therapy or prophylaxis of conditions associated with abnormal gene expression.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: July 24, 2012
    Assignee: 4SC Discovery GmbH
    Inventors: Alexander B. Maurer, Sascha Hoevelmann, Elke Martin, Bernd Hentsch, Michael Gassen, Juergen Kraus, Rolf Krauss, Adam-Spencer Vincek
  • Patent number: 8222295
    Abstract: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: July 17, 2012
    Assignee: Centre de Recherche sur les Biotechnologies Marines
    Inventor: Samuel Fortin
  • Publication number: 20120171310
    Abstract: Novel plant essential oil-based antimicrobial filming compositions that are useful in protecting, repairing and strengthening the natural slime coat found on fish are disclosed, which compositions are comprised of a mixture of plant essential oils having antimicrobial properties, filming agents, and surfactants.
    Type: Application
    Filed: December 23, 2011
    Publication date: July 5, 2012
    Applicant: Sergeant's Pet Care Products, Inc.
    Inventors: Colin G. Brodie, Ralph Van Blarcom
  • Patent number: 8207230
    Abstract: The present invention relates generally to pharmacological methods for the amelioration of sleep-related breathing disorders via administration of inhibitors of endocannabinoid membrane transport and combinations thereof.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: June 26, 2012
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: David W. Carley, Miodrag Radulovacki
  • Patent number: 8202893
    Abstract: One aspect of this disclosure relates generally to lipid compounds that exert diverse effects in the endocannabinoid system, such as regulating CB1 and CB2 receptor or moderating other bio-macromolecules within the endocannabinoid system. Some of the compounds showed improved receptor binding affinity, and/or improved receptor subtype selectivity, and improved bio-stability. Some of the compounds exhibit activities to regulate the enzymes that moderate the bio-disposal of endogenous cannabinoids, such as the fatty acid amide hydrolase (FAAH). Some of the compounds exhibit activities to inhibit the anandamide transporter. Other aspects of the invention are pharmaceutical preparations employing these ligands and methods of administering therapeutically effective amounts of the preparations to provide a physiological effect.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: June 19, 2012
    Assignee: University of Connecticut
    Inventors: Alexandros Makriyannis, Chen Li, Dai Lu
  • Publication number: 20120148604
    Abstract: The present invention, relates to methods including compounds, derivatives, antibodies, interfering RNA, biologies, polypeptides, dominant negative effectors, and their use in the treatment of neuropathic pain by inhibition of transient receptor potential (TRP) channels. In another embodiment, this invention relates to inhibitors, antagonists, and agonists of TRPC4. TRPC4 therapeutic agents and modulators include but are not limited to small molecule inhibitors, compounds, amino acid derivatives, polypeptides, RNA interference agents, natural chemicals, ligand derivatives, and ions. TRPC4 therapeutic agents and modulators are developed for the treatment of neuropathic pain, including but not limited to pain sensations such as nociception, hyperalgesia, allodynia, and loss of sensory function.
    Type: Application
    Filed: August 20, 2010
    Publication date: June 14, 2012
    Applicant: TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
    Inventors: Eric M. Ostertag, John Stuart Crawford
  • Patent number: 8188313
    Abstract: Compounds of formula wherein the variable are defined in the specification, are used in compositions which stimulate T cell responses.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: May 29, 2012
    Assignees: The University of Birmingham, Chancellor Masters and Scholars of the University of Oxford, Ludwig Institute for Cancer Research
    Inventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
  • Publication number: 20120122990
    Abstract: The present invention relates to the field of liquid crystals. Embodiments of the present invention relate to liquid crystals comprising at least one molecule within N-acyl ethanolamide (NAE) family, for example oleoylethanolamide (OEA), compositions comprising them and their possible uses.
    Type: Application
    Filed: March 30, 2009
    Publication date: May 17, 2012
    Applicant: NESTEC S.A.
    Inventors: Rafaele Mezzenga, Sayed Mohammady, Matthieu Pouzot
  • Publication number: 20120121680
    Abstract: Deicing products designed to deter ungulates are provided, along with methods of using those products to treat iced surfaces. The deicing product comprises a mixture of a deicer along with an ungulate repellent. The repellent can repel based on conditioned avoidance, fear, chemical irritation, and/or bad taste. The deicer can be a salt or a deicer solution. The invention is useful for deterring any ungulate that might be attracted to a component of the deicing product (e.g., the salt), but it is particularly useful for deterring deer.
    Type: Application
    Filed: October 18, 2011
    Publication date: May 17, 2012
    Applicant: NORTH AMERICAN SALT COMPANY
    Inventors: Neil Alexander Rosenburgh, Michelle Lee Daum, Jason Louis Bagley, Dan Pannell, Kristopher Shelite
  • Publication number: 20120093888
    Abstract: A formulation to treat rheumatic disorders and related infections is provided. The formulation is a micro-emulsion including at one or more of an active ingredients. The active ingredient includes one or more of an essential oil mixed with an aqueous phase along with one or more of a surfactant and one or more of a co-surfactant. The co-surfactant is medicated by an extract of one or more of an herb.
    Type: Application
    Filed: June 4, 2010
    Publication date: April 19, 2012
    Inventors: Manu Chaudhary, Vijay Naithani
  • Publication number: 20120087874
    Abstract: The present invention includes compositions for imparting a controlled-release warming sensation to the oral receptor areas of a user. The oral, controlled-release warming compositions include a warming agent and a hydrated or swollen food-grade polymer which forms a matrix with the warming agent. Also included are oral delivery systems for the warming compositions, methods for preparing same, and methods for imparting and sustaining a warming sensation in the mouth and upper portion of the gastrointestinal tract of the user.
    Type: Application
    Filed: December 9, 2011
    Publication date: April 12, 2012
    Inventors: Jamileh Lakkis, Susan Pettigrew
  • Publication number: 20120077822
    Abstract: An in situ film-forming sprayable methyl acetate-based solution of at least one absorbable, low-crystallinity, segmented copolymer contains at least one bioactive agent, which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane and the bioactive solution thereof can be applied onto animal and human skin or accessible body cavities to prevent or treat one or more disorder susceptible to the bioactive agent therein.
    Type: Application
    Filed: January 29, 2011
    Publication date: March 29, 2012
    Inventors: Shalaby W. Shalaby, Joel T. Corbett, Jason Olbrich
  • Publication number: 20120070507
    Abstract: Provided herein are compositions and methods for the treatment of soft tissue injury, sports-related injury, physical overuse of muscles, ligaments or joints, and trauma, traumatic stress or sudden jolts on bones and tissues in an individual. Described herein are pharmaceutical compositions comprising a vasoconstrictor and, optionally, a topical analgesic and methods of using said compositions for the treatment of a variety of soft tissue injuries.
    Type: Application
    Filed: September 17, 2010
    Publication date: March 22, 2012
    Applicant: MATRILINEX LLC
    Inventors: Corinna HOWELL, Neil HOWELL
  • Publication number: 20120071417
    Abstract: Methods of inhibiting cancer cell growth using HDAC10 inhibitors are provided. Methods of treating cancer in a subject using HDAC10 inhibitors are also provided. In certain embodiments, at least one second inhibitor selected from an autophagy inhibitor, an AMPK inhibitor, and methyl pyruvate is also used in the methods. Dose packs comprising HDAC10 inhibitors and at least one second inhibitor are provided. Methods of identifying HDAC10 inhibitors are also provided.
    Type: Application
    Filed: November 10, 2009
    Publication date: March 22, 2012
    Inventors: Tso-pang Yao, Hitoshi Sasajima, Yoshiharu Kawaguchi, Kai Cui, Chun-Hsiang Lai
  • Publication number: 20120064177
    Abstract: The present invention relates to a method of preparing an intranasal composition including from about 0.0010-0.0040% by weight capsaicin, from about 0.50-0.90% by weight hydroxypropyl methylcellulose, from about 0.010-0.080% by weight n-alkyl dimethyl benzyl ammonium chloride (Quat), and various moisturizing and irrigation agents, wherein the method includes dissolving the above components in water to form an aqueous solution; and filtering the aqueous solution to form an intranasal composition. The present invention further relates to an intranasal drug delivery composition, which includes from about 0.0010-0.0040% by weight capsaicin, from about 0.50-0.90% by weight hydroxypropyl methylcellulose, from about 0.010-0.080% by weight n-alkyl dimethyl benzyl ammonium chloride (Quat), and various moisturizing and irrigation agents.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 15, 2012
    Inventor: Paul Carpenter
  • Publication number: 20120058208
    Abstract: The present disclosure relates to a composition to enhance the bioavailability of curcumin. In one embodiment, a composition comprising plant extracts of curcumin, vanilla and ginger, wherein the extracts of ginger and vanilla are rich in gingerol and vanillin respectively, is provided. In other embodiments, curcumin, and one or more items selected from the group of vanilla, ginger and capsaicin is provided.
    Type: Application
    Filed: April 8, 2011
    Publication date: March 8, 2012
    Applicant: SYNTHITE INDUSTRIES LTD.
    Inventor: Chennakattu Varkey Jacob
  • Publication number: 20120040021
    Abstract: The invention relates to compositions comprising an acid ceramidase inhibitor and a choline kinase inhibitor as well as to the uses thereof for the treatment of cancer. The invention also relates to methods for the selection of an individualised therapy of a cancer patient based on the detection of the acid ceramidase levels. Moreover, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent and uses thereof for the treatment of cancer. Finally, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent or a death receptor ligand and uses thereof for the treatment of cancer.
    Type: Application
    Filed: August 12, 2011
    Publication date: February 16, 2012
    Applicant: TRASLATIONAL CANCER DRUGS PHARMA, S.L.
    Inventors: Ana Ramirez De Molina, Lourdes Garcia Oroz, Juan Carlos Lacal Sanjuan
  • Publication number: 20120028906
    Abstract: A method for affecting the timing of cervical ripening and the resultant onset of parturition in a pregnant female mammal, the method comprises administering to a pregnant female one or more than one dose of an agent that chemically mimics innervation of the cervix by the vagus nerve, thereby advancing the onset of parturition, or administering to a pregnant female one or more than one dose of an agent that chemically blocks innervation of the cervix by the vagus nerve, thereby delaying the onset of parturition.
    Type: Application
    Filed: March 10, 2010
    Publication date: February 2, 2012
    Applicant: LOMA LINDA UNIVERSITY
    Inventor: Steven M. Yellon
  • Publication number: 20120027693
    Abstract: The methods and compositions of the present invention are directed to the treatment or amelioration of muscle cramps using a composition that includes one or more TRPV1 channel activators, and/or one or more TRPA1 channel activators, and/or one or more ASIC channel activators.
    Type: Application
    Filed: July 27, 2011
    Publication date: February 2, 2012
    Inventors: Bruce P. Bean, Donald MacKinnon, Roderick MacKinnon
  • Publication number: 20120022105
    Abstract: Grease-like compositions are provided for repelling rodents. The compositions utilize nontoxic mineral, synthetic, or vegetable oil based gels containing silica, clay, urea, polytetrafluoroethylene, or metallic soap thickeners and capsaicin.
    Type: Application
    Filed: October 6, 2011
    Publication date: January 26, 2012
    Applicants: Tomlin Scientific, Inc., PiGNX, Inc.
    Inventors: Richard Numata, Ryan Willey
  • Publication number: 20120022165
    Abstract: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-30 fatty alcohol, monoglyceride or the reaction products thereof.
    Type: Application
    Filed: September 30, 2011
    Publication date: January 26, 2012
    Applicant: MICRODERMIS CORPORATION
    Inventors: Griscom Bettle, III, William S. Coury
  • Publication number: 20120016032
    Abstract: Cosmetic compositions comprising calcium citrate and at least one N-acylated aminoalcohol according to formula (I). Provided is a method of treating aged skin, comprising topically applying to the aged skin a composition comprising a compound of Formula (I) in an amount effective to provide an anti-ageing effect. The compound of Formula (I) is used to prevent skin and/or to help to maintain or improve moisture retention and/or to fight against the signs of skin ageing. The N-acylated aminoalcohol of formula (I) acts as a ceramidase inhibitor. The combination of at least one compound of formula (I) and calcium citrate stimulates keratinocyte differentiation.
    Type: Application
    Filed: March 16, 2010
    Publication date: January 19, 2012
    Applicant: Cognis IP Management GmbH
    Inventors: Philippe Moussou, Olga Freis, Louis Danoux, Philippe Grisoni, Laurent Bailly
  • Publication number: 20120009240
    Abstract: The present disclosure relates to self-supporting films for delivery of a therapeutic agent containing at least one hydrophobic polymer and at least one therapeutic agent. Methods of forming the multilayer films are also disclosed.
    Type: Application
    Filed: June 30, 2011
    Publication date: January 12, 2012
    Inventors: Joshua Stopek, Daniel Broom, Amin Elachchabi, Garrett Ebersole
  • Publication number: 20110313047
    Abstract: The present invention is directed to a delivery system capable of solubilizing high concentrations of ceramide, the system containing: (a) at least one C1-C4 monoalcohol; (b) at least one C6-C22 fatty acid and/or alcohol; and (c) from about 5 to about 14% by weight, based on the weight of the composition, of at least one ceramide.
    Type: Application
    Filed: May 20, 2011
    Publication date: December 22, 2011
    Applicant: L'OREAL S.A.
    Inventor: Marc CORNELL
  • Publication number: 20110301078
    Abstract: A group of antimicrobial compounds shows effectiveness for preventing bacterial growth and bio film formation. In particular, the compounds are effective for preventing the growth of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (“MRSA”) bacteria. The compounds include naturally-occurring compounds such as linoleyl ethanolamide, noladin ether, and anandamide, and man-made compounds such as CP55,640 [(?)-cis-3-[2-Hydroxy-4-(l,l-dimethylheptyl)phenyl]-tran s-4-(3-hydroxypropyl)cyclohexanol] and O-2050 [(6aR,10aR)-3-(l-Methanesulfonylamino-4-hexyn-6-yl)-6a, 7,10,1 Oa-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran]. Because these antibacterial compounds have unique modes of action and/or unique chemical scaffolds compared to traditional antibiotics, they are extremely useful against bacteria having resistances to antibiotics.
    Type: Application
    Filed: June 25, 2009
    Publication date: December 8, 2011
    Inventors: John A. Schetz, Sally A. Hoger
  • Publication number: 20110256510
    Abstract: Disclosed are compositions and methods of using such compositions for inhibiting matrix metalloproteinase activity in dental tissue. The compositions, methods and uses may prevent degradation of the bonding between restorative materials and dental tissues, thereby increasing durability and longevity of the restorative material-dental tissue bonds. For example, the compositions, methods, and uses of the present invention may be used for treating carious dental tissue such as by the creation of dental fillings, crowns, bridges, among other techniques, as well as the creation of esthetic laminate restorations.
    Type: Application
    Filed: January 11, 2010
    Publication date: October 20, 2011
    Inventors: David Henry Pashley, Franklin Chin-Meng Tay, Milena Cadenaro
  • Patent number: 8039670
    Abstract: There are disclosed compound of formula I, in which R1 represents a hydrophobic moiety adapted to occupy the C? channel of human CDId, R2 represents a hydrophobic moiety adapted to occupy the A? channel of human CDId, such that R1 fills at least at least 30% of the occupied volume of the C? channel compared to the volume occupied by the terminal nC14H29 of the sphingosine chain of ?-galactosylceramide when bound to human CDId and R2 fills at least 30% of the occupied volume of the A? channel compared to the volume occupied by the terminal nC25H51 of the acyl chain of ?-galactosylceramide when bound to human CDId R3 represents hydrogen or OH, Ra and Rb each represent hydrogen and in addition, when R3 represents hydrogen, Ra and Rb together may form a single bond, X represents or —CHA(CHOH)nY or —P(=0)(0?)0CH2(CH0H)mY, in which Y represents CHB1B2, n represents an integer from 1 to 4, m represents 0 or 1, A årepresents hydrogen, one of B1 and B2 represents H, OH or phenyl, and the other represents hydrogen or o
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: October 18, 2011
    Assignees: Ludwig Institute for Cancer Research, Chancellor Master and Scholars of the University of Oxford, The University of Birmingham
    Inventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
  • Publication number: 20110251241
    Abstract: Grease-like compositions are provided for repelling rodents. The compositions utilize nontoxic mineral, synthetic, or vegetable oil based gels containing silica, clay, urea, polytetrafluoroethylene, or metallic soap thickeners and capsaicin.
    Type: Application
    Filed: April 7, 2011
    Publication date: October 13, 2011
    Applicants: Tomlin Scientific Inc., PiGNX, Inc.
    Inventors: Richard Numata, Ryan Willey
  • Publication number: 20110236459
    Abstract: Surgical implants of the present disclosed include a film comprising a first therapeutic agent and a mesh comprising a second therapeutic agent. The surgical implant includes a film in direct contact with a mesh. The first therapeutic agent may be released at a first rate and the second therapeutic agent may be released at a second rate.
    Type: Application
    Filed: March 18, 2011
    Publication date: September 29, 2011
    Inventors: Joshua Stopek, Amin Elachchabi, Daniel Broom, Garrett Ebersole